• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Vivos Therapeutics Expands Product Line and Revenue Potential with Acquisition of Product Rights and Patents from Advanced Facialdontics, Llc

Share:

March 7, 2023

Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical device and technology company that delivers training and a full line of highly effective proprietary oral appliances for the treatment of breathing related sleep disorders, including mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, today announced it has acquired certain U.S. and international patents, product rights, and other miscellaneous intellectual property from Advanced Facialdontics, LLC (“AFD”), a company holding propriety technology on certain FDA 510(k) cleared dental and medical devices.

With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product portfolio and revenue potential.

AFD’s flagship product, the Preventive Oral Device®, known as the POD®, is a custom single arch device with an FDA 510(k) clearance for treating an estimated 40 million patients in the U.S. and Canada with Temporomandibular Joint Dysfunction (TMD) and/or Bruxism (teeth grinding or clenching), both known to be closely associated with OSA. Studies have shown that there is a clear connection between OSA and TMD.

AFD’s second FDA 510(k) cleared product, known as the Night Block™, is a custom dual-arch mandibular advancement oral appliance that incorporates patented unilateral bite block technology, which can alleviate or eliminate many of the downsides of traditional oral appliance treatment such as inflammation of the TMJ, facial pain, neck pain, headaches, tension, fatigue, clenching, and grinding.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

The acquisition of these novel technologies, patent portfolio and product rights further enhance Vivos’ existing intellectual property and technology base, enabling Vivos to provide new, complementary products to many OSA patients who experience pain, discomfort, headaches, tooth loss, and other symptoms associated with TMD and Bruxism.

In addition, this acquisition will provide Vivos providers with an additional treatment option for patients who do not have OSA, but suffer from jaw pain, headaches, and daytime fatigue. Vivos expects to be able to manufacture the AFD products through existing manufacturing relationships.

Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer, commented “This acquisition adds important technology and products that immediately open up new markets to us with significant revenue potential. We can now offer dentists and patients a complete line of lower cost products with higher margins alongside our existing Vivos Method treatments to meet whatever clinical needs and financial price points they may require. In this transaction, we have also acquired several U.S. and international patents, some of which were granted in just the past few months that will allow us to preserve and protect our first mover advantages in the U.S. and Canada as well as other international markets. TMD and Bruxism are very common, but often difficult to treat. We believe this highly effective technology from AFD is a real breakthrough, with significant applications across many different kinds of existing oral appliances, such as clear aligners, palatal expanders, and traditional mandibular advancement devices, as well as our own CARE devices that are part of The Vivos Method.”

In connection with this transaction, Dr. Scott Simonetti, DDS, the founder and CEO of AFD and the inventor of the acquired patents, has been appointed as Vivos’ new Senior Director of Research and Product Development. Dr. Simonetti said, “I am elated to join the Vivos team with our company’s novel line of products and technology. Vivos is widely regarded throughout the dental profession as a leading provider of highly effective treatments through The Vivos Method for certain debilitating conditions associated with breathing related sleep disorders. I’m confident our current and future products will fit well into Vivos’ existing technology platform to provide a broad range of products and services to patients who suffer from OSA.”

For further information, including transaction terms, please refer to Vivos’ Current Report on Form 8-K regarding this transaction that will be filed with the Securities and Exchange Commission.

Source: Biospace

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • PHC Holdings Signs Agreement to Acquire Anatomical Pathology Business from Thermo Fisher ScientificPHC Holdings Signs Agreement to Acquire Anatomical Pathology Business from Thermo Fisher Scientific
  • Vitamins and Minerals Market Trends, Insights and Forecast 2020 – 2027Vitamins and Minerals Market Trends, Insights and Forecast 2020 – 2027
  • Global Pulmonary Sarcoidosis Pipeline Insight Market Report 2021 Featuring Novartis, aTyr Pharma, Relief Therapeutics, AI Therapeutics, & SarcoMed USAGlobal Pulmonary Sarcoidosis Pipeline Insight Market Report 2021 Featuring Novartis, aTyr Pharma, Relief Therapeutics, AI Therapeutics, & SarcoMed USA
  • Tusk Therapeutics to be acquired by RocheTusk Therapeutics to be acquired by Roche
  • Kakao Healthcare Partners with Novo Nordisk for Digital Diabetes ServiceKakao Healthcare Partners with Novo Nordisk for Digital Diabetes Service
  • Modi Cabinet approves 100% FDI in medical devices sector via automatic routeModi Cabinet approves 100% FDI in medical devices sector via automatic route
  • VC Funding in Digital Health Hits $5.1 Billion in 1H 2019VC Funding in Digital Health Hits $5.1 Billion in 1H 2019
  • Odyssey Investment Partners To Acquire ProPharma GroupOdyssey Investment Partners To Acquire ProPharma Group

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications